However, many problems still need to be resolved, including the lack of clearly available data in breast cancer, notably regarding PD-1 expression and its prognostic value, and the application of PD-1/PD-L1 inhibitors in combination with other immune checkpoint inhibitors. Here, PDCD1 is linked to breast cancer.